Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

New York State Psychiatric Institute

Status and phase: Completed; Phase 2; Phase 1

Conditions: Cannabis Use

Treatments: Drug: Lorcaserin; Drug: Marijuana; Drug: Placebo

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT03253926

7475

Details and patient eligibility

About

In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.

Full description

In order to improve treatment outcome for cannabis use disorder (CUD), the investigators have developed a laboratory model to investigate the effects of potential treatment medications on cannabis withdrawal and on the subjective and reinforcing effects of cannabis in non treatment-seeking cannabis smokers. In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.

Enrollment: 15 patients

Sex: All

Ages: 21 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Current cannabis use
• Able to give informed consent and perform study procedures
• Women practicing an effective form of birth control
• English speaking

Exclusion criteria

• Presence of any clinically significant medical diagnoses
• History of heart disease and cardiac risk factors, severe chronic obstructive pulmonary disease, uncontrolled hypertension, or diabetes
• Current parole or probation
• Certain psychiatric diagnoses
• Current pregnancy or lactation

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

15 participants in 2 patient groups, including a placebo group

Lorcaserin + Marijuana

Experimental group

Treatment:

Drug: Marijuana

Drug: Lorcaserin

Placebo + Marijuana

Placebo Comparator group

Treatment:

Drug: Placebo

Drug: Marijuana